VenatoRx Pharmaceuticals
PrivateLast Round
Grant
Oct 10, 2023
Total Funding Raised
$329.5M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
VenatoRx Pharmaceuticals operates in Healthcare & Life Sciences and is based in Malvern, Pennsylvania. Its latest recorded funding round was a Grant round in October 2023.
VenatoRx Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of novel anti-infective agents to treat multi-drug-resistant bacterial and viral infections.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Government Contracts, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
VenatoRx Pharmaceuticals Comparables
Compare VenatoRx Pharmaceuticals with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Allecra Therapeutics | 90% | |
| Antabio | 87% | |
| Fedora Pharmaceuticals Inc. | 85% |
For institutional investors. Book with your work email.
VenatoRx Pharmaceuticals Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Oct 10, 2023 | ||||
| VC Round | Dec 1, 2022 | ||||
| Grant | Oct 3, 2022 | ||||
| Series C | Apr 4, 2022 | ||||
| Grant | Jul 27, 2020 | ||||
Grant | Nov 25, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
VenatoRx Pharmaceuticals Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| AMR Action Fund | Series C |
| National Institute of Allergy and Infectious Diseases | Grant |
| CARB-X | Grant |
| Public Health Emergency Medical Countermeasures Enterprise | Grant |
| Foresite Capital | Series B |
| Versant Ventures | Series B |
| Abingworth | Series B, Series C |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 31% MoM.
- Oct 10, 2023
$167M grant awarded by BARDA and PHEMCE.
For institutional investors. Book with your work email.
VenatoRx Pharmaceuticals Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about VenatoRx Pharmaceuticals's valuation, stock price, and market status.
Is VenatoRx Pharmaceuticals a public or private company?
VenatoRx Pharmaceuticals is a private company.
What is the current stock price of VenatoRx Pharmaceuticals?
VenatoRx Pharmaceuticals is a private company, so its shares have no public market price. Caplight tracks VenatoRx Pharmaceuticals's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is VenatoRx Pharmaceuticals worth (valuation)?
Valuation information for VenatoRx Pharmaceuticals is not publicly available.
Can I buy VenatoRx Pharmaceuticals stock?
VenatoRx Pharmaceuticals shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was VenatoRx Pharmaceuticals's last funding round?
VenatoRx Pharmaceuticals's most recent funding round was Grant on October 10, 2023.
Who are the main investors in VenatoRx Pharmaceuticals?
Key investors in VenatoRx Pharmaceuticals include AMR Action Fund, Versant Ventures.
Will VenatoRx Pharmaceuticals IPO soon?
No public IPO plans have been announced for VenatoRx Pharmaceuticals.
How can I track VenatoRx Pharmaceuticals secondary market activity?
Caplight tracks bids, offers, and trades in VenatoRx Pharmaceuticals's shares on secondary markets.